These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 31145505)
1. Taurolidine-citrate lock solution for the prevention of central line-associated bloodstream infection in paediatric haematology-oncology and gastrointestinal failure patients with high baseline central-line associated bloodstream infection rates. Chong CY; Ong RY; Seah VX; Tan NW; Chan MY; Soh SY; Ong C; Lim AS; Thoon KC J Paediatr Child Health; 2020 Jan; 56(1):123-129. PubMed ID: 31145505 [TBL] [Abstract][Full Text] [Related]
2. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial. Tribler S; Brandt CF; Petersen AH; Petersen JH; Fuglsang KA; Staun M; Broebech P; Moser CE; Jeppesen PB Am J Clin Nutr; 2017 Sep; 106(3):839-848. PubMed ID: 28793993 [No Abstract] [Full Text] [Related]
3. The CATERPILLAR study: an assessor-blinded randomized controlled trial comparing a taurolidine-citrate-heparin lock solution to a heparin-only lock solution for the prevention of central-line-associated bloodstream infections in paediatric oncology patients. van den Bosch CH; Loeffen YGT; van der Steeg AFW; van der Bruggen JT; Frakking FNJ; Fiocco M; van de Ven CP; Wijnen MHWA; van de Wetering MD J Hosp Infect; 2024 Oct; 152():56-65. PubMed ID: 39004189 [TBL] [Abstract][Full Text] [Related]
4. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT). Gudiol C; Nicolae S; Royo-Cebrecos C; Aguilar-Guisado M; Montero I; Martín-Gandul C; Perayre M; Berbel D; Encuentra M; Arnan M; Cisneros-Herreros JM; Carratalà J Trials; 2018 May; 19(1):264. PubMed ID: 29720244 [TBL] [Abstract][Full Text] [Related]
5. A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients. Gudiol C; Arnan M; Aguilar-Guisado M; Royo-Cebrecos C; Sánchez-Ortega I; Montero I; Martín-Gandul C; Laporte-Amargós J; Albasanz-Puig A; Nicolae S; Perayre M; Berbel D; Tebe C; Riera J; Sureda A; Cisneros JM; Carratalà J Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712211 [TBL] [Abstract][Full Text] [Related]
6. Use of 2% taurolidine lock solution for treatment and prevention of catheter-related bloodstream infections in neonates: a feasibility study. Savarese I; Yazami S; De Rose DU; Carkeek K; Campi F; Auriti C; Danhaive O; Piersigilli F J Hosp Infect; 2024 Jan; 143():76-81. PubMed ID: 37972710 [TBL] [Abstract][Full Text] [Related]
7. Central venous catheter-associated bloodstream infections in pediatric hematology-oncology patients and effectiveness of antimicrobial lock therapy. Tsai HC; Huang LM; Chang LY; Lee PI; Chen JM; Shao PL; Hsueh PR; Sheng WH; Chang YC; Lu CY J Microbiol Immunol Infect; 2015 Dec; 48(6):639-46. PubMed ID: 25311403 [TBL] [Abstract][Full Text] [Related]
8. Peripherally inserted central catheters are associated with lower risk of bloodstream infection compared with central venous catheters in paediatric intensive care patients: a propensity-adjusted analysis. Yamaguchi RS; Noritomi DT; Degaspare NV; Muñoz GOC; Porto APM; Costa SF; Ranzani OT Intensive Care Med; 2017 Aug; 43(8):1097-1104. PubMed ID: 28584925 [TBL] [Abstract][Full Text] [Related]
9. Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock. Chu HP; Brind J; Tomar R; Hill S J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):403-7. PubMed ID: 22595973 [TBL] [Abstract][Full Text] [Related]
10. The effect of the multimodal intervention including an automatic notification of catheter days on reducing central line-related bloodstream infection: a retrospective, observational, quasi-experimental study. Bae S; Kim Y; Chang HH; Kim S; Kim HJ; Jeon H; Cho J; Lee J; Chae H; Han G; Kim SW BMC Infect Dis; 2022 Jul; 22(1):604. PubMed ID: 35804323 [TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. Dümichen MJ; Seeger K; Lode HN; Kühl JS; Ebell W; Degenhardt P; Singer M; Geffers C; Querfeld U J Hosp Infect; 2012 Apr; 80(4):304-9. PubMed ID: 22342714 [TBL] [Abstract][Full Text] [Related]
12. Epidemiology of Infectious and Noninfectious Catheter Complications in Patients Receiving Home Parenteral Nutrition: A Systematic Review and Meta-Analysis. Reitzel RA; Rosenblatt J; Chaftari AM; Raad II JPEN J Parenter Enteral Nutr; 2019 Sep; 43(7):832-851. PubMed ID: 31172542 [TBL] [Abstract][Full Text] [Related]
13. Asymptomatic central line-associated bloodstream infections in children implanted with long term indwelling central venous catheters in a teaching hospital, Sri Lanka. Jayaweera JAAS; Sivakumar D BMC Infect Dis; 2020 Jun; 20(1):457. PubMed ID: 32600427 [TBL] [Abstract][Full Text] [Related]
14. Management of enterococcal central line-associated bloodstream infections in patients with cancer. Awadh H; Chaftari AM; Khalil M; Fares J; Jiang Y; Deeba R; Ali S; Hachem R; Raad II BMC Infect Dis; 2021 Jul; 21(1):643. PubMed ID: 34225651 [TBL] [Abstract][Full Text] [Related]
15. The best solution down the line: an observational study on taurolidine- versus citrate-based lock solutions for central venous catheters in hemodialysis patients. van Roeden S; van Oevelen M; Abrahams AC; Dekker FW; Rotmans JI; Meijvis SCA; BMC Nephrol; 2021 Sep; 22(1):308. PubMed ID: 34517829 [TBL] [Abstract][Full Text] [Related]
16. Impact of a Best Practice Prevention Bundle on Central Line-associated Bloodstream Infection (CLABSI) Rates and Outcomes in Pediatric Hematology, Oncology, and Hematopoietic Cell Transplantation Patients in Inpatient and Ambulatory Settings. Ardura MI; Bibart MJ; Mayer LC; Guinipero T; Stanek J; Olshefski RS; Auletta JJ J Pediatr Hematol Oncol; 2021 Jan; 43(1):e64-e72. PubMed ID: 32960848 [TBL] [Abstract][Full Text] [Related]
17. Cefazolin-gentamicin versus taurolidine-citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial. Bueloni TNV; Marchi D; Caetano C; de Souza Cavalcante R; Mendes Amaral ML; Ponce D Int J Infect Dis; 2019 Aug; 85():16-21. PubMed ID: 31102823 [TBL] [Abstract][Full Text] [Related]
18. The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis. van den Bosch CH; Jeremiasse B; van der Bruggen JT; Frakking FNJ; Loeffen YGT; van de Ven CP; van der Steeg AFW; Fiocco MF; van de Wetering MD; Wijnen MHWA J Hosp Infect; 2022 May; 123():143-155. PubMed ID: 34767871 [TBL] [Abstract][Full Text] [Related]
19. CATERPILLAR-study protocol: an assessor-blinded randomised controlled trial comparing taurolidine-citrate-heparin to heparin-only lock solutions for the prevention of central line-associated bloodstream infections in paediatric oncology patients. van den Bosch CH; Loeffen Y; van der Steeg AFW; van der Bruggen JT; Frakking FNJ; Fiocco M; van de Ven CP; Wijnen MHWA; van de Wetering MD BMJ Open; 2023 Mar; 13(3):e069760. PubMed ID: 36944461 [TBL] [Abstract][Full Text] [Related]
20. Duration of central venous catheter placement and central line-associated bloodstream infections after the adoption of prevention bundles: a two-year retrospective study. Pitiriga V; Bakalis J; Kampos E; Kanellopoulos P; Saroglou G; Tsakris A Antimicrob Resist Infect Control; 2022 Jul; 11(1):96. PubMed ID: 35841083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]